The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies
Raúl Córdoba, MD, PhD, Fundación Jiménez Díaz, Madrid, Spain, discusses an analysis of the pharmacokinetics (PK) and pharmacodynamics (PD) of odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), based on the ELM-1 (NCT02290951) and ELM-2 (NCT03888105) studies. The results support the current dosing regimen and confirm T-cell activation and B-cell depletion in response to the drug. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
